Celebrating our CBEE students at the GEARS (Graduate Experience, Achievements & Research Symposium) 2024. Sahar Souizi, Environmental Engineering PhD student in Dr. Blaney’s Lab, clinched the runner-up title, and Revati Kadolkar, Chemical and Biochemical Engineering PhD, under Dr. Frey & CAST, seized the People's Choice Award. 

Congratulations Sahar and Revati, for your outstanding achievements!

GEARS provides a platform for students to showcase their creative achievements, present research accomplishments, and share their experiences with peers. GEARS aims to provide a friendly atmosphere to promote collaboration, improve communication skills, and celebrate the hard work of UMBC graduate students.

Research led by Dr. Govind Rao, Director of Center for Advanced Sensor Technology and professor in the department of Chemical, Biochemical and Environmental Engineering is featured in a recent article posted on leaps.org titled “With This New Technology, Hospitals and Pharmacies Could Make Vaccines and Medicines Onsite, 2023” The story was written based on a preprint of a paper with Shayan Borhani, Chemical Engineering PhD candidate as the first author. Aaron Thole, Chemical Engineering PhD student and Dr. Doug Frey, professor in the department of Chemical, Biochemical and Environmental Engineering are also co-authors. (https://www.biorxiv.org/content/10.1101/2022.12.19.521044v1).

The article describes a process to develop a compelling pandemic mitigation strategy to promptly suppress viral emergence at the source of an outbreak using proteins such as GRFT which are efficacious in neutralizing a broad range of viruses. This process is shown to produce a product with consistent purity and potency in less than 24 hours using cell-free biomanufacturing. 

The collaborators demonstrated GRFT production using two independent cell-free systems, one plant and one microbial. Griffithsin purity and quality were verified using standard regulatory metrics. Efficacy was demonstrated in vitro against SARS-CoV-2 and HIV-1 and was nearly identical to that of GRFT expressed in vivo. The proposed production process is efficient and can be readily scaled up and deployed anywhere in the world where a viral pathogen might emerge. The current emergence of viral variants has resulted in frequent updating of existing vaccines and loss of efficacy for front-line monoclonal antibody therapies.

Dr. Rao wants to advance technology to the point where any hospital or pharmacy could load up the media containing molecular factories, mix up the necessary amino acids, nucleotides, and enzymes, and harvest the medications in a matter of hours. This will enable on-site and on-demand medication production. Once this approach is thoroughly validated it might revolutionize medicine-making even outside of hospitals and pharmacies and extend beyond urgent situations.

Dr. Rao, Dr. Frey and graduate students from the Chemical Biochemical & Environmental Engineering Department (CBEE) at UMBC as well as collaborators, released a transcript in bioRxiv, titled: “An approach to rapid distributed manufacturing of broad spectrum anti-viral griffithsin using cell-free systems to mitigate pandemics”.

The study details a way for swiftly and effectively synthesizing a protein with broad-spectrum activity. The protein, known as griffithsin, can now be made using either a plant-based or microbial cell-free technology in less than 24 hours and is effective against viruses like SARS-CoV-2 and HIV-1 in vitro. 

The production process is effective and scalable, and its quality and purity have been confirmed using accepted regulatory metrics. Being able to quickly deploy it anywhere in the world to aid in containing viral outbreaks at their source makes it a crucial tool for pandemic mitigation. The development of viral variants has resulted in frequent updates to current vaccines and decreased efficacy of some monoclonal antibody treatments, making proteins like griffithsin a potential asset to the suite of antiviral therapies.